Who is sponsoring NCT02113176?

NCT02113176 is sponsored by University at Buffalo.

What condition does NCT02113176 study?

NCT02113176 studies Subarachnoid Aneurysm Hemorrhage.

What is the status of NCT02113176?

NCT02113176 is currently WITHDRAWN.

Last reviewed 2025-07-17 · How we verify

Minocycline as Neuroprotectant After Aneurysmal Subarachnoid Hemorrhage

NCT02113176 Phase 1/Phase 2 WITHDRAWN

The purpose of this study is to determine the safety and efficacy of a drug minocycline in improving outcomes at 3 months after rupture of an aneurysm in the head.

Details

Lead sponsor	University at Buffalo
Phase	Phase 1/Phase 2
Status	WITHDRAWN
Start date	2010-01
Completion	2018-12

Conditions

Subarachnoid Aneurysm Hemorrhage

Interventions

Minocycline

Primary outcomes

adverse event — 21 days
The primary objective of the study is to evaluate the effectiveness of minocycline in improving outcomes for patients after aneurysmal SAH. To determine the safety of minocycline 200mg/day for 21 days in the treatment arm after aneurysmal subarachnoid hemorrhage.

Countries

United States